DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)

Information source: Hillerod Hospital, Denmark
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Major Depression

Intervention: escitalopram (Drug); escitalopram (Drug); escitalopram (Drug); nortriptyline (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: Hillerod Hospital, Denmark

Official(s) and/or principal investigator(s):
Klaus Martiny, MD,PhD, Principal Investigator, Affiliation: Mental Health Center Copenhagen Department O


The main purpose of this study is to investigate the relapse preventing efficacy of escitalopram in a dose range and nortriptylin in a single dose in patients having been treated successfully with a course of electroconvulsive treatment (ECT).

Clinical Details

Official title: Relapse Prevention in Patients With a Major Depressive Episode Treated With Electroconvulsive Treatment Using a Fixed Dose Range of Escitalopram Compared to a Fixed Dose of Nortriptyline (DUAG-7) A Randomised Controlled 6 Month Double-blind Study

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Hamilton depression rating scale

Secondary outcome: Drop out due to side-effects of drugs

Detailed description: This study records severity of depression and relapse in patients treated for a major depressive disorder with electroconvulsive treatment (ECT)in a period og 6 month after end of ECT treatment. Patients will be randomized into four groups treated with escitalopram 10 mg, 20 mg, 30 mg or nortriptylin 100 mg daily dosages. The primary outcome measure is relapse and secondary outcome measure is tolerability. The study is a multicenter trial within Denmark.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Remission from a major depressive episode after ECT treatment

Exclusion Criteria:

- Suicidality (Hamilton item 3 score of 3 or more)

- Symptoms mania (MAS score of 15 or more)

- Duration of actual depressive episode more than 2 years

- Compulsory measures of any kind

- Dementia

- Severe somatic illness

- Pregnant or lactating subject

- Known clinical relevant malabsorption.

- Epilepsia

- Clinically substantial cognitive deterioration due to ECT treatment

- schizophrenia, schizopreniform or schizo-affective disorder

- Bipolar I, Bipolar II eller

- Rapid cycling bipolar disorder

- Abuse of alcohol or drugs

- Early relapse (less than 2 month) after ECT

- Inadequate contraception

- Known intolerance to any of the used study medications

- Myocardial infarction in the last 6 month

- Clinical important liver disease

- Any known disturbance of the cardiac conduction system, cardiac insufficiency,or

other clinical important cardiac disease

- Treatment with a MAO-inhibitor

- Treatment with norepinephrine or epinephrine

- Known hyperthyroidism or treatment with thyroid hormones

- Known ortostatic hypertension.

- Glaucoma

- Known hereditary galactoseintolerance, Lapp Lactase deficiency) or


- Ongoing treatment with sympatomimetica efedrine, isoprenaline, physostigmine,

dopamine, levodopa, phenylephrine.

- Ongoing treatment with anticholinergica, antiparkinson treatment, antihistamines,

atropine, biperiden,

- Ongoing treatment with drugs that prolongs the cardiac QT-interval, such as

quinidine, antihistamines, terfenadine og sotalole

- Ongoing treatment with fluconazole or terbinafine

- Ongoing treatment with mefloquin.

- Known intolerance to escitalopram

- Ongoing treatment with serotonergic acting substances such as tramadole, sumatriptane

Locations and Contacts

Mental Health Centre Copenhagen Department O, Copenhagenl 2100 Ø, Denmark
Additional Information

homepage for the DUAG organization

Related publications:

Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, Crowe RR, Cooper TB, Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001 Mar 14;285(10):1299-307.

Starting date: August 2009
Last updated: December 7, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017